Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (31-40 of 209) with videos related to

Pageof 21
Sort By:
Lung Cancer (Amsterdam, Netherlands)|January 4, 2006
Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysisIsabelle Borget, Patrick Tilleul, Mariette Baud, et al.
Lung Cancer Management|March 21, 2025
Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLCChristos Chouaid, Francesco Grossi, Christine Ta Thanh Minh, et al.
Respiratory Medicine|December 7, 2010
Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007Claire Fuhrman, Nicolas Roche, Alain Vergnenègre, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 20, 2024
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and CostsTess Martin, Catherine Rioufol, Bertrand Favier, et al.
Journal of Market Access & Health Policy|August 15, 2017
Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessmentMondher Toumi, Anastasiia Motrunich, Aurélie Millier, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Lung cancer survivors and employment: A systematic reviewFlora Vayr, Frédéric Savall, Laurence Bigay-Game, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2020
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutationThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2010
Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay studyMélisande Bernard, Mélanie Brignone, Alain Adehossi, et al.
Journal of Thoracic Disease|August 3, 2018
Lung cancer and interstitial lung disease: a literature reviewJean-Marc Naccache, Quentin Gibiot, Isabelle Monnet, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 11, 2017
Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in FranceMaud Pignata, Christos Chouaid, Katell Le Lay, et al.
Pageof 21

Showing results (31-40 of 209) with videos related to

Sort By:
Pageof 21
Lung Cancer (Amsterdam, Netherlands)|January 4, 2006
Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysisIsabelle Borget, Patrick Tilleul, Mariette Baud, et al.
Lung Cancer Management|March 21, 2025
Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLCChristos Chouaid, Francesco Grossi, Christine Ta Thanh Minh, et al.
Respiratory Medicine|December 7, 2010
Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007Claire Fuhrman, Nicolas Roche, Alain Vergnenègre, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 20, 2024
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and CostsTess Martin, Catherine Rioufol, Bertrand Favier, et al.
Journal of Market Access & Health Policy|August 15, 2017
Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessmentMondher Toumi, Anastasiia Motrunich, Aurélie Millier, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Lung cancer survivors and employment: A systematic reviewFlora Vayr, Frédéric Savall, Laurence Bigay-Game, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2020
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutationThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2010
Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay studyMélisande Bernard, Mélanie Brignone, Alain Adehossi, et al.
Journal of Thoracic Disease|August 3, 2018
Lung cancer and interstitial lung disease: a literature reviewJean-Marc Naccache, Quentin Gibiot, Isabelle Monnet, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 11, 2017
Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in FranceMaud Pignata, Christos Chouaid, Katell Le Lay, et al.
Pageof 21